NCT07892196Recruiting
Does Chronic Pain Change Over Time in Children With Duchenne Muscular Dystrophy?
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
1\. Brief Summary This prospective observational study aims to evaluate the 6-month longitudinal changes in chronic pain, pain characteristics, coping strategies, and functional performance in children and adolescents aged 7 to 18 years diagnosed with Duchenne Muscular Dystrophy (DMD), with a primary focus on comparing ambulatory and non-ambulatory disease stages. Pediatric DMD patients followed at the University of Health Sciences Antalya Training and Research Hospital Neuromuscular Diseases Center will undergo comprehensive evaluations at baseline (Month 0) and at 6 months follow-up (Month 6). Pain parameters will be evaluated using the Adolescent Pediatric Pain Tool (APPT) to assess pain intensity, body localization, and sensory/affective/evaluative/temporal qualities, and the Brief Pain Inventory (BPI) 7-item Pain Interference Scale to determine pain interference with daily activities. Pain coping strategies will be assessed using the Pediatric Pain Coping Inventory (PPCI, adolescent and parent versions). Functional and motor assessments will include the North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT), stair climb/descend tests, Vignos and Brooke scales, handgrip dynamometry, manual muscle testing (MMT), and range of motion (ROM) and contracture evaluations, alongside anthropometrics and quality of life. The central hypotheses are that non-ambulatory patients experience chronic pain more frequently, with longer duration, greater intensity, and across a higher number of anatomical sites than ambulatory patients. Furthermore, the study hypothesizes that anatomical pain sites, pain-aggravating and pain-relieving factors, and pain coping mechanisms differ significantly between ambulatory and non-ambulatory stages.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 17 Oct 2026
- Start date
- 2 Jan 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Antalya Training and Research Hospital
- Diseases
- Duchenne muscular dystrophy
- NCT number
- NCT07892196
What you commit to
- Study type: Observational
- Planned participants: 30
- From 2 Jan 2026 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of tracheostomy
- Severe speech or communication impairment preventing self-report assessments
- Presence of co-existing psychiatric or neurodevelopmental conditions (e.g., autism spectrum disorder, attention deficit hyperactivity disorder \[ADHD\])
Other
- Bedridden status (inability to sit or maintain basic seated posture)
- Severe intellectual disability that precludes understanding instructions
Who the study is looking for
- Genetically confirmed diagnosis of Duchenne Muscular Dystrophy (DMD)
- Aged 7 to 18 years
- Residing in Antalya, Turkey (geographical restriction applied to minimize patient travel burden and prevent loss to follow-up over the 6-month observation period)
- Intact hearing and vision capability sufficient to complete test instructions and self-report forms
- Voluntary willingness to participate, with signed informed consent from parents/legal guardians and informed assent from the child
Age in the registry: 7 years to 18 years · Sex: Male
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Health Sciences Antalya Training and Research Hospital, Neuromuscular Diseases Center Coordinator of this site? Confirm its status | Antalya | Turkey (Türkiye) | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.